- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
HP inks catheter deal with Guidant
Hewlett-Packard has signed an agreement with Guidant of Indianapolisgiving that cardiology device company rights to distribute coronaryand peripheral intravascular ultrasound catheters that HP haslicensed from Boston Scientific. HP executed the deal
Hewlett-Packard has signed an agreement with Guidant of Indianapolisgiving that cardiology device company rights to distribute coronaryand peripheral intravascular ultrasound catheters that HP haslicensed from Boston Scientific. HP executed the deal becauseit believes that Guidant's distribution channels are more suitedfor the IVUS market than its own, according to the Andover, MA,company.
HP gained access to the catheters through an agreement lastyear with Boston Scientific, which at the time was preparing tobuy catheter developers Cardiovascular Imaging Systems and ScimedLife Systems. To avoid a monopoly in the IVUS market, the FederalTrade Commission required Boston Scientific to enter a consentdecree in which it licensed the technology to a third party, Hewlett-Packard(SCAN 3/15/95).
HP already has a deal with Guidant for development of guideddirectional atherectomy catheters. Guidant also has rights todistribute Hewlett-Packard's Sonos Intravascular Ultrasound Systemwith the catheters.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
